Assessing unused residual Pfizer-BioNTech COVID-19 vaccine: a community observational study
Stephen Hubbard, Rajlaxmi Bais
doi: https://doi.org/10.1101/2021.08.03.21261569
Stephen Hubbard
Bainbridge Prepares, Bainbridge Island, WA
MD, FACCRajlaxmi Bais
Bainbridge Prepares, Bainbridge Island, WA
DNP, ARNPArticle usage
Posted August 09, 2021.
Assessing unused residual Pfizer-BioNTech COVID-19 vaccine: a community observational study
Stephen Hubbard, Rajlaxmi Bais
medRxiv 2021.08.03.21261569; doi: https://doi.org/10.1101/2021.08.03.21261569
Subject Area
Subject Areas
- Addiction Medicine (390)
- Allergy and Immunology (705)
- Anesthesia (195)
- Cardiovascular Medicine (2874)
- Dermatology (244)
- Emergency Medicine (431)
- Epidemiology (12597)
- Forensic Medicine (10)
- Gastroenterology (809)
- Genetic and Genomic Medicine (4470)
- Geriatric Medicine (405)
- Health Economics (717)
- Health Informatics (2865)
- Health Policy (1056)
- Hematology (378)
- HIV/AIDS (905)
- Medical Education (418)
- Medical Ethics (115)
- Nephrology (465)
- Neurology (4226)
- Nursing (226)
- Nutrition (619)
- Oncology (2215)
- Ophthalmology (629)
- Orthopedics (255)
- Otolaryngology (321)
- Pain Medicine (269)
- Palliative Medicine (83)
- Pathology (488)
- Pediatrics (1180)
- Primary Care Research (485)
- Public and Global Health (6810)
- Radiology and Imaging (1499)
- Respiratory Medicine (904)
- Rheumatology (430)
- Sports Medicine (372)
- Surgery (474)
- Toxicology (59)
- Transplantation (204)
- Urology (175)